Related Experiment Video

Updated: Mar 23, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.8K

Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction

Gerd Heusch1, Petra Kleinbongard2

  • 1West German Heart and Vascular Center, Institute for Pathophysiology, University of Essen Medical School, Hufelandstr. 55, 45122, Essen, Germany. gerd.heusch@uk-essen.de.

Drugs
|April 5, 2016
PubMed

Insights

Ivabradine, a heart rate-lowering drug, benefits patients with heart failure and reduces heart damage in animal models. It shows potential for vascular and anti-aging effects, independent of heart rate reduction.

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • Ivabradine targets hyperpolarization-activated cyclic nucleotide-gated channels in the sinus node, reducing heart rate.
  • Heart rate reduction improves myocardial blood flow and function in ischemic conditions.
  • Previous studies show ivabradine's benefits in stable coronary artery disease and heart failure.

Purpose of the Study:

  • To investigate the effects of ivabradine on myocardial ischemia/reperfusion injury in animal models.
  • To explore potential heart rate-independent mechanisms of ivabradine's action.
  • To assess ivabradine's impact on vascular function and its anti-aging potential.

Main Methods:

  • Administering ivabradine to pigs and mice subjected to myocardial ischemia/reperfusion.
  • Utilizing atrial pacing to abrogate heart rate reduction during ischemia/reperfusion.
  • Examining isolated ventricular cardiomyocytes under simulated ischemia/reperfusion.
  • Assessing vascular function in mice and pigs, and left ventricular function in pigs.

Main Results:

  • Ivabradine reduced infarct size in myocardial ischemia/reperfusion in pigs and mice, irrespective of heart rate changes.
  • Improved cardiomyocyte viability was observed following simulated ischemia/reperfusion.
  • Evidence suggests heart rate-independent benefits in vasculature and left ventricular function.
  • Ivabradine demonstrated anti-aging potential in mice.

Conclusions:

  • Ivabradine offers cardioprotective effects against ischemia/reperfusion injury, potentially through reduced mitochondrial reactive oxygen species.
  • The drug exhibits heart rate-independent benefits in the vasculature and cardiac function.
  • Ivabradine presents potential therapeutic applications beyond heart rate reduction, including anti-aging.

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.1K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.6K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.2K